EGFR and squamous cell lung carcinoma: However, an IIIB Squamous cell lung cancer (SqCLC) patient harboring EGFR Exon 19 E746_S752delinsV mutation could benefit from targeted therapies of gefitinib, and no evidence of disease was found for up to 20 months, which indicated that the first-generation EGFR TKIs might be a good choice for advanced SqCLC patients and different types of uncommon exon 19 mutations have a different response to TKIs (23).